Targeting the insulin-regulated aminopeptidase/AT4 receptor for cognitive disorders.


The insulin-regulated aminopeptidase/AT(4) receptor has recently emerged as a new target for pharmaceutical agents aimed at treating various cognitive disorders such as Alzheimer's disease. There is an unmet need for metabolically stable drug-like angiotensin (Ang) IV analogues that exert actions mimicking the powerful memory-enhancing effects of Ang IV and… (More)
DOI: 10.1358/dnp.2009.22.3.1325032


  • Presentations referencing similar topics